These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 3956687)

  • 21. A role for Old Yellow Enzyme in ergot alkaloid biosynthesis.
    Cheng JZ; Coyle CM; Panaccione DG; O'Connor SE
    J Am Chem Soc; 2010 Feb; 132(6):1776-7. PubMed ID: 20102147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abundant respirable ergot alkaloids from the common airborne fungus Aspergillus fumigatus.
    Panaccione DG; Coyle CM
    Appl Environ Microbiol; 2005 Jun; 71(6):3106-11. PubMed ID: 15933008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conformation of dopamine at the dopamine receptor.
    Komiskey HL; Bossart JF; Miller DD; Patil PN
    Proc Natl Acad Sci U S A; 1978 Jun; 75(6):2641-3. PubMed ID: 275833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Guanine nucleotides reveal differential actions of ergot derivatives at D-2 receptors labelled by [3H]spiperone in striatal homogenates.
    Gundlach AL; Krstich M; Beart PM
    Brain Res; 1983 Nov; 278(1-2):155-63. PubMed ID: 6227373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biosynthetic pathways of ergot alkaloids.
    Gerhards N; Neubauer L; Tudzynski P; Li SM
    Toxins (Basel); 2014 Dec; 6(12):3281-95. PubMed ID: 25513893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ergot alkaloid biosynthesis in Aspergillus fumigatus: Conversion of chanoclavine-I aldehyde to festuclavine by the festuclavine synthase FgaFS in the presence of the old yellow enzyme FgaOx3.
    Wallwey C; Matuschek M; Xie XL; Li SM
    Org Biomol Chem; 2010 Aug; 8(15):3500-8. PubMed ID: 20526482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bromocriptine, a dopamine D(2) receptor agonist with the structure of the amino acid ergot alkaloids, induces neurite outgrowth in PC12 cells.
    Oda T; Kume T; Izumi Y; Takada-Takatori Y; Niidome T; Akaike A
    Eur J Pharmacol; 2008 Nov; 598(1-3):27-31. PubMed ID: 18835264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ergot and its alkaloids.
    Schiff PL
    Am J Pharm Educ; 2006 Oct; 70(5):98. PubMed ID: 17149427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aminopyrimidines with high affinity for both serotonin and dopamine receptors.
    Wustrow D; Belliotti T; Glase S; Kesten SR; Johnson D; Colbry N; Rubin R; Blackburn A; Akunne H; Corbin A; Davis MD; Georgic L; Whetzel S; Zoski K; Heffner T; Pugsley T; Wise L
    J Med Chem; 1998 Feb; 41(5):760-71. PubMed ID: 9513604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LSD labels a novel dopamine receptor in molluscan nervous system.
    Drummond AH; Bucher F; Levitan IB
    Nature; 1978 Mar; 272(5651):368-70. PubMed ID: 24805
    [No Abstract]   [Full Text] [Related]  

  • 31. Functional analysis of the gene controlling hydroxylation of festuclavine in the ergot alkaloid pathway of Neosartorya fumigata.
    Bilovol Y; Panaccione DG
    Curr Genet; 2016 Nov; 62(4):853-860. PubMed ID: 26972831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ergot drugs and central monoaminergic mechanisms: a histochemical, biochemical and behavioral analysis.
    Fuxe K; Fredholm BB; Ogren SO; Agnati LF; Hökfelt T; Gustafsson JA
    Fed Proc; 1978 Jun; 37(8):2181-91. PubMed ID: 350633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopaminergic 2-aminotetralins: affinities for dopamine D2-receptors, molecular structures, and conformational preferences.
    Johansson AM; Karlén A; Grol CJ; Sundell S; Kenne L; Hacksell U
    Mol Pharmacol; 1986 Sep; 30(3):258-69. PubMed ID: 2943981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
    Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA
    J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conformational analysis of the ergot alkaloids ergotamine and ergotaminine.
    Pierri L; Pitman IH; Rae ID; Winkler DA; Andrews PR
    J Med Chem; 1982 Aug; 25(8):937-42. PubMed ID: 7120281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of bromerguride, a new dopamine-antagonistic ergot derivative in rat and dog.
    Hilderbrand M; Hümpel M; Krause W; Täuber U
    Eur J Drug Metab Pharmacokinet; 1987; 12(1):31-40. PubMed ID: 3609071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The molecular architecture of ergopeptines: a basis for biological interaction.
    Weber HP
    Adv Biochem Psychopharmacol; 1980; 23():25-34. PubMed ID: 6249091
    [No Abstract]   [Full Text] [Related]  

  • 38. Degradation and epimerization of ergot alkaloids after baking and in vitro digestion.
    Merkel S; Dib B; Maul R; Köppen R; Koch M; Nehls I
    Anal Bioanal Chem; 2012 Nov; 404(8):2489-97. PubMed ID: 22968686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new semisynthetic ergot peptide alkaloid: DCN 203-922.
    Giger RK; Loosli HR; Walkinshaw MD; Clark BJ; Vigouret JM
    Experientia; 1987 Oct; 43(10):1125-30. PubMed ID: 2959497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple receptors for dopamine.
    Kebabian JW; Calne DB
    Nature; 1979 Jan; 277(5692):93-6. PubMed ID: 215920
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.